Symbols / NMRA Stock $2.26 +0.22% Neumora Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
NMRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NMS · United States
Market Cap 411.96M
Enterprise Value 282.07M
Income -236.93M
Sales —
FCF (ttm) -115.71M
Book/sh 0.60
Cash/sh 1.00
Employees 96
Insider 10d —
IPO Sep 14, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.44
PEG —
P/S —
P/B 3.78
P/C —
EV/EBITDA -1.20
EV/Sales —
Quick Ratio 5.62
Current Ratio 5.87
Debt/Eq 52.96
LT Debt/Eq —
EPS (ttm) -1.45
EPS next Y -0.92
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-03-30
ROA -58.11%
ROE -121.21%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 182.69M
Shs Float 104.83M
Insider Own 23.93%
Instit Own 56.01%
Short Float 4.27%
Short Ratio 3.78
Short Interest 4.47M
52W High 3.65
vs 52W High -38.22%
52W Low 0.61
vs 52W Low 269.07%
Beta 3.12
Impl. Vol. 7.90%
Rel Volume 0.55
Avg Volume 1.34M
Volume 738.34K
Target (mean) $8.91
Tgt Median $7.63
Tgt Low $3.00
Tgt High $18.00
# Analysts 8
Recom None
Prev Close $2.25
Price $2.25
Change 0.22%
About

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.91
Mean price target
2. Current target
$2.26
Latest analyst target
3. DCF / Fair value
$-11.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.26
Low
$3.00
High
$18.00
Mean
$8.91

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 reit Guggenheim Buy → Buy $14
2026-03-31 reit Needham Buy → Buy $8
2026-02-17 up William Blair Market Perform → Outperform —
2026-01-12 init Leerink Partners — → Outperform $8
2025-12-01 up RBC Capital Sector Perform → Outperform $7
2025-11-17 main Stifel Hold → Hold $3
2025-10-28 main Needham Buy → Buy $8
2025-10-27 up Guggenheim Neutral → Buy $14
2025-09-16 down JP Morgan Neutral → Underweight —
2025-07-16 main Mizuho Outperform → Outperform $5
2025-05-13 reit Needham Buy → Buy $5
2025-04-10 reit Needham Buy → Buy $5
2025-04-02 down B of A Securities Buy → Underperform $1
2025-03-10 down Guggenheim Buy → Neutral —
2025-03-07 down Stifel Buy → Hold $2
2025-03-07 reit HC Wainwright & Co. Buy → Buy $18
2025-03-04 reit RBC Capital Sector Perform → Sector Perform $4
2025-03-04 reit Needham Buy → Buy $5
2025-03-04 main HC Wainwright & Co. Buy → Buy $18
2025-02-14 reit HC Wainwright & Co. Buy → Buy $30
News
RSS: Latest NMRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-17 BERNS PAUL L Chief Executive Officer — 9,819 $3.51 $34,459
2026-02-17 AURORA DALJIT SINGH Chief Operating Officer — 6,165 $3.56 $21,917
2026-02-17 PINTO JOSHUA PH.D. President — 5,967 $3.54 $21,093
2026-02-17 MILLIGAN MICHAEL LEE Chief Financial Officer — 1,436 $3.56 $5,119
2025-11-11 AURORA DALJIT SINGH Chief Operating Officer — 114,703 $2.68 $307,026
2025-10-27 BUROW KRISTINA M Director and Beneficial Owner of more than 10% of a Class of Security — 1,915,700 $2.61 $4,999,977
2025-10-27 ARCH VENTURE PARTNERS XII, LLC Beneficial Owner of more than 10% of a Class of Security — 1,915,700 $2.61 $4,999,977
2025-05-21 PINTO JOSHUA PH.D. President — 13,202 $0.00 $0
2025-02-18 BERNS PAUL L Chief Executive Officer — 13,871 $1.69 $23,468
2025-02-18 AURORA DALJIT SINGH Officer — 8,565 $1.68 $14,347
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
241.16
-8.47%
263.46
+4.51%
252.10
+85.54%
135.87
Research And Development
181.06
-9.89%
200.93
-2.76%
206.62
+97.26%
104.75
Selling General And Administration
60.09
-3.91%
62.54
+37.52%
45.48
+46.12%
31.12
General And Administrative Expense
60.09
-3.91%
62.54
+37.52%
45.48
+46.12%
31.12
Other Gand A
60.09
-3.91%
62.54
+37.52%
45.48
+46.12%
31.12
Total Expenses
241.16
-8.47%
263.46
+4.51%
252.10
+85.54%
135.87
Operating Income
-241.16
+8.47%
-263.46
-4.51%
-252.10
-85.54%
-135.87
Total Operating Income As Reported
-241.16
+8.47%
-263.46
-4.51%
-252.10
-85.54%
-135.87
EBITDA
-233.37
+11.21%
-262.83
-4.54%
-251.43
-85.86%
-135.28
Normalized EBITDA
-233.37
+11.21%
-262.83
-4.54%
-251.43
-85.86%
-135.28
Reconciled Depreciation
0.21
-67.04%
0.63
-5.54%
0.67
+12.46%
0.59
EBIT
-233.58
+11.34%
-263.46
-4.51%
-252.10
-85.54%
-135.87
Net Income
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Pretax Income
-236.80
+2.80%
-243.61
-3.37%
-235.66
-80.02%
-130.90
Net Non Operating Interest Income Expense
5.12
-74.29%
19.93
+20.00%
16.61
+264.20%
4.56
Interest Expense Non Operating
3.22
—
—
—
Net Interest Income
5.12
-74.29%
19.93
+20.00%
16.61
+264.20%
4.56
Interest Expense
3.22
—
—
—
Interest Income Non Operating
8.34
-58.14%
19.93
+20.00%
16.61
+264.20%
4.56
Interest Income
8.34
-58.14%
19.93
+20.00%
16.61
+264.20%
4.56
Other Income Expense
-0.77
-883.33%
-0.08
+54.12%
-0.17
-141.98%
0.41
Other Non Operating Income Expenses
-0.77
-883.33%
-0.08
+54.12%
-0.17
-141.98%
0.41
Tax Provision
0.13
-26.97%
0.18
-33.58%
0.27
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Net Income From Continuing Operation Net Minority Interest
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Net Income From Continuing And Discontinued Operation
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Net Income Continuous Operations
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Normalized Income
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Net Income Common Stockholders
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Diluted EPS
-1.45
+5.23%
-1.53
+57.85%
-3.63
-321.36%
-0.86
Basic EPS
-1.45
+5.23%
-1.53
+57.85%
-3.63
-321.36%
-0.86
Basic Average Shares
163.39
+2.52%
159.38
+145.12%
65.02
-57.21%
151.95
Diluted Average Shares
163.39
+2.52%
159.38
+145.12%
65.02
-57.21%
151.95
Diluted NI Availto Com Stockholders
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
191.05
-39.73%
316.97
-36.12%
496.19
+16.41%
426.23
Current Assets
190.54
-39.33%
314.06
-34.34%
478.28
+23.28%
387.95
Cash Cash Equivalents And Short Term Investments
182.53
-40.66%
307.58
-32.25%
453.98
+22.08%
371.88
Cash And Cash Equivalents
182.53
+28.41%
142.15
-62.00%
374.04
+55.24%
240.94
Other Short Term Investments
0.00
-100.00%
165.43
+106.93%
79.94
-38.95%
130.94
Receivables
—
—
0.94
+2.18%
0.92
Other Receivables
—
—
0.94
+2.18%
0.92
Prepaid Assets
—
—
23.36
+54.67%
15.10
Restricted Cash
0.00
-100.00%
1.21
0.00
-100.00%
0.05
Other Current Assets
8.01
+52.11%
5.26
-78.33%
24.30
—
Total Non Current Assets
0.51
-82.52%
2.92
-83.72%
17.92
-53.20%
38.28
Net PPE
0.46
-84.33%
2.92
-57.47%
6.86
-35.56%
10.64
Gross PPE
0.64
-87.03%
4.97
-40.12%
8.29
-29.13%
11.70
Accumulated Depreciation
-0.19
+90.87%
-2.05
-42.79%
-1.44
-35.38%
-1.06
Properties
—
—
0.00
0.00
Machinery Furniture Equipment
0.23
-34.20%
0.34
-10.16%
0.38
-30.94%
0.56
Construction In Progress
0.00
0.00
-100.00%
0.04
-92.02%
0.51
Other Properties
0.42
-90.98%
4.62
-41.27%
7.87
-25.88%
10.62
Leases
—
—
0.00
-100.00%
0.02
Investments And Advances
—
0.00
-100.00%
9.85
-58.13%
23.51
Non Current Deferred Assets
—
—
—
2.91
Non Current Prepaid Assets
—
—
—
0.00
Other Non Current Assets
0.05
—
1.21
-70.60%
4.13
Total Liabilities Net Minority Interest
87.18
+191.48%
29.91
+10.28%
27.12
-96.89%
873.08
Current Liabilities
32.45
+8.58%
29.89
+19.02%
25.11
+5.97%
23.70
Payables And Accrued Expenses
20.67
+15.33%
17.93
+54.75%
11.58
+12.64%
10.28
Payables
3.38
+2.18%
3.31
+881.31%
0.34
-95.28%
7.15
Accounts Payable
3.38
+2.18%
3.31
+881.31%
0.34
-95.28%
7.15
Current Accrued Expenses
17.29
+18.31%
14.62
+29.98%
11.25
+258.61%
3.14
Pensionand Other Post Retirement Benefit Plans Current
11.49
+15.23%
9.97
-0.36%
10.01
+19.18%
8.40
Current Debt And Capital Lease Obligation
0.28
-84.67%
1.85
-45.15%
3.38
+0.24%
3.37
Current Capital Lease Obligation
0.28
-84.67%
1.85
-45.15%
3.38
+0.24%
3.37
Other Current Liabilities
—
0.13
-4.32%
0.14
-91.55%
1.64
Total Non Current Liabilities Net Minority Interest
54.73
+248650.00%
0.02
-98.90%
2.01
-99.76%
849.39
Long Term Debt And Capital Lease Obligation
54.73
0.00
-100.00%
1.85
-63.47%
5.07
Long Term Debt
54.53
—
—
—
Long Term Capital Lease Obligation
0.19
0.00
-100.00%
1.85
-63.47%
5.07
Other Non Current Liabilities
—
0.02
-85.81%
0.15
-75.32%
0.63
Preferred Securities Outside Stock Equity
0.00
0.00
0.00
-100.00%
843.69
Stockholders Equity
103.87
-63.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Common Stock Equity
103.87
-63.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Capital Stock
0.02
+6.25%
0.02
+0.00%
0.02
+433.33%
0.00
Common Stock
0.02
+6.25%
0.02
+0.00%
0.02
+433.33%
0.00
Share Issued
174.26
+7.76%
161.71
+1.81%
158.83
+4.53%
151.95
Ordinary Shares Number
174.26
+7.76%
161.71
+1.81%
158.83
+4.53%
151.95
Additional Paid In Capital
1,288.00
+4.36%
1,234.21
+5.26%
1,172.57
+5371.63%
21.43
Retained Earnings
-1,184.15
-25.01%
-947.22
-34.66%
-703.43
-50.46%
-467.51
Gains Losses Not Affecting Retained Earnings
0.00
-100.00%
0.06
+181.58%
-0.08
+90.18%
-0.77
Other Equity Adjustments
—
0.06
+181.58%
-0.08
+90.18%
-0.77
Total Equity Gross Minority Interest
103.87
-63.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Total Capitalization
158.40
-44.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Working Capital
158.09
-44.37%
284.17
-37.29%
453.17
+24.41%
364.26
Invested Capital
158.40
-44.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Total Debt
55.01
+2868.65%
1.85
-64.58%
5.23
-38.04%
8.44
Capital Lease Obligations
0.48
-74.26%
1.85
-64.58%
5.23
-38.04%
8.44
Net Tangible Assets
103.87
-63.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Tangible Book Value
103.87
-63.82%
287.06
-38.80%
469.08
+204.97%
-446.85
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-206.44
-12.85%
-182.94
-12.04%
-163.28
-42.11%
-114.90
Cash Flow From Continuing Operating Activities
-206.44
-12.85%
-182.94
-12.04%
-163.28
-42.11%
-114.90
Net Income From Continuing Operations
-236.93
+2.81%
-243.79
-3.33%
-235.93
-80.23%
-130.90
Depreciation Amortization Depletion
0.21
-67.04%
0.63
-5.54%
0.67
+12.46%
0.59
Depreciation And Amortization
0.21
-67.04%
0.63
-5.54%
0.67
+12.46%
0.59
Other Non Cash Items
3.13
-5.43%
3.31
-95.08%
67.38
+339.50%
15.33
Stock Based Compensation
29.88
-25.29%
39.99
+131.96%
17.24
+107.76%
8.30
Asset Impairment Charge
0.59
0.00
—
—
Operating Gains Losses
0.05
—
—
-0.56
Gain Loss On Investment Securities
—
—
—
-0.56
Unrealized Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
0.05
0.00
—
—
Change In Working Capital
-0.44
-101.93%
22.64
+354.37%
-8.90
-28.08%
-6.95
Change In Prepaid Assets
-2.77
-117.42%
15.90
+239.51%
-11.40
-214.25%
-3.63
Change In Payables And Accrued Expense
4.27
-57.80%
10.11
+71.19%
5.91
+305.96%
-2.87
Change In Accrued Expense
4.20
-42.03%
7.24
+11.56%
6.49
+500.12%
-1.62
Change In Payable
0.07
-97.53%
2.87
+594.49%
-0.58
+53.37%
-1.25
Change In Account Payable
0.07
-97.53%
2.87
+594.49%
-0.58
+53.37%
-1.25
Change In Other Current Assets
-0.05
0.00
0.00
-100.00%
1.37
Change In Other Current Liabilities
-1.88
+44.35%
-3.38
+0.73%
-3.40
-86.36%
-1.83
Investing Cash Flow
168.52
+338.84%
-70.56
-209.58%
64.39
+138.32%
-168.01
Cash Flow From Continuing Investing Activities
168.52
+338.84%
-70.56
-209.58%
64.39
+138.32%
-168.01
Net PPE Purchase And Sale
0.22
0.00
+100.00%
-0.12
+77.10%
-0.51
Purchase Of PPE
—
0.00
+100.00%
-0.12
+77.10%
-0.51
Sale Of PPE
0.22
0.00
—
—
Capital Expenditure
—
—
-0.12
+77.10%
-0.51
Net Investment Purchase And Sale
168.30
+341.18%
-69.78
-201.00%
69.09
+144.72%
-154.50
Purchase Of Investment
-82.87
+73.46%
-312.22
-186.25%
-109.07
+51.82%
-226.37
Sale Of Investment
251.17
+3.60%
242.44
+36.08%
178.17
+147.91%
71.87
Net Other Investing Changes
—
-0.78
+83.12%
-4.59
+64.69%
-13.00
Financing Cash Flow
77.09
+256.84%
21.60
-90.69%
231.94
+100.39%
115.74
Cash Flow From Continuing Financing Activities
77.09
+256.84%
21.60
-90.69%
231.94
+100.39%
115.74
Net Issuance Payments Of Debt
57.16
0.00
—
—
Issuance Of Debt
57.16
0.00
—
—
Long Term Debt Issuance
57.16
0.00
—
—
Net Long Term Debt Issuance
57.16
0.00
—
—
Net Common Stock Issuance
19.65
+43.52%
13.69
-94.12%
232.88
0.00
Common Stock Payments
—
0.00
+100.00%
-0.49
0.00
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.49
0.00
Proceeds From Stock Option Exercised
0.28
-96.52%
7.91
+176.93%
2.86
-33.13%
4.27
Net Other Financing Charges
—
—
-3.80
-411.29%
-0.74
Changes In Cash
39.17
+116.89%
-231.89
-274.29%
133.04
+179.59%
-167.17
Beginning Cash Position
143.36
-61.80%
375.25
+54.93%
242.21
-40.83%
409.37
End Cash Position
182.53
+27.32%
143.36
-61.80%
375.25
+54.93%
242.21
Free Cash Flow
-206.44
-12.85%
-182.94
-11.96%
-163.40
-41.58%
-115.41
Interest Paid Supplemental Data
1.50
0.00
—
—
Income Tax Paid Supplemental Data
0.32
-31.71%
0.47
—
—
Amortization Of Securities
-2.93
+48.70%
-5.72
-52.87%
-3.74
-428.39%
-0.71
Common Stock Issuance
19.65
+43.52%
13.69
-94.13%
233.38
0.00
Issuance Of Capital Stock
19.65
+43.52%
13.69
-94.13%
233.38
+107.97%
112.22
Net Preferred Stock Issuance
—
0.00
0.00
-100.00%
112.22
Preferred Stock Issuance
—
0.00
0.00
-100.00%
112.22
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category